<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02321514</url>
  </required_header>
  <id_info>
    <org_study_id>CS-03</org_study_id>
    <nct_id>NCT02321514</nct_id>
  </id_info>
  <brief_title>Expanded Clinical Study of the Tendyne Mitral Valve System</brief_title>
  <official_title>Expanded Clinical Study of the Tendyne Mitral Valve System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and performance of the Tendyne Mitral&#xD;
      Valve System in the treatment of severe mitral regurgitation in patents with functional&#xD;
      disability greater than or equal to NYHA Class II, who are not suitable candidates for&#xD;
      surgical replacement with otherwise available devices. Follow-up evaluations will be&#xD;
      conducted through 5 years post implantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Actual">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Endpoint: Number of Participants With Composite of Device Success and Freedom From Device or Procedure Related Serious Adverse Events (SAEs)</measure>
    <time_frame>30 days post-index procedure</time_frame>
    <description>Device success and freedom from the following device- or procedure-related serious adverse events (SAEs) at 30 days post the index procedure, will be classified by the Clinical Events Committee (CEC):&#xD;
Cardiovascular death&#xD;
Reintervention caused by valve-related dysfunction&#xD;
Disabling stroke&#xD;
Myocardial infarction (MI)&#xD;
Life-threatening bleeding (BARC Type 2, 3, and 5)&#xD;
Major Vascular Complications&#xD;
Renal failure requiring dialysis&#xD;
Other device-related SAEs&#xD;
Other procedure-related SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance Endpoint: Number of Participants With MR Grade ≤ 2</measure>
    <time_frame>30 days post-index procedure</time_frame>
    <description>Proportion of subjects with mitral regurgitation (MR) grade ≤ 2, per echocardiography core laboratory will be assessed.&#xD;
MR severity is graded on a scale of 0+ to 4+ where 0+ means absence of mitral regurgitation, 1+ is mild, 2+ is moderate, 3+ is moderate-to-severe and 4+ is severe.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">191</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>Tendyne Mitral Valve System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo transcatheter mitral valve replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tendyne Mitral Valve System</intervention_name>
    <description>Patients will undergo transcatheter mitral valve replacement using Tendyne Mitral Valve system</description>
    <arm_group_label>Tendyne Mitral Valve System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Severe mitral regurgitation of primary or secondary etiology according to MVARC&#xD;
             (Mitral Valve Academic Research Consortium) 2015 defined as:&#xD;
&#xD;
               -  For Degenerative MR: EROA ≥ 40 mm^2 or regurgitant volume ≥ 60ml&#xD;
&#xD;
               -  For Secondary MR: EROA ≥ 20 mm^2 or regurgitant volume ≥ 30ml&#xD;
&#xD;
          2. New York Heart Association (NYHA) functional Class ≥ II while on guideline directed&#xD;
             medical therapy (GMDT), including device therapy (CRT) if indicated.&#xD;
&#xD;
          3. Heart team determines patient is not a suitable candidate for traditional surgical&#xD;
             treatment according to valid guidelines.&#xD;
&#xD;
          4. Age 18 years or older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe mitral annular calcification, severe mitral stenosis, valvular vegetation or&#xD;
             mass.&#xD;
&#xD;
          2. Left Ventricle (LV) or Left Atrium (LA) thrombus.&#xD;
&#xD;
          3. Patient has a chest condition that prevents transapical access.&#xD;
&#xD;
          4. Left ventricular ejection fraction (LVEF) less than 30% by echocardiogram.&#xD;
&#xD;
          5. Left Ventricular End Diastolic Diameter (LVEDD) &gt; 7.0 cm.&#xD;
&#xD;
          6. Prior surgical or interventional treatment of mitral or aortic valves (e.g. valve&#xD;
             repair or replacement, MitraClip, edge to edge repair, aortic balloon valvuloplasty,&#xD;
             etc.).&#xD;
&#xD;
          7. Any planned surgery or interventional procedure within the period of 30 days prior to&#xD;
             30 days following the implant procedure. This includes any planned concomitant&#xD;
             cardiovascular procedure such as PCI, pulmonary vein ablation, left atrial appendage&#xD;
             occlusion, septal defect repair, etc.&#xD;
&#xD;
          8. Cardiac resynchronization therapy device or implantable pulse generator implanted&#xD;
             within three months of planned implant procedure.&#xD;
&#xD;
          9. Myocardial Infarction (MI) within 30 days of the planned implant procedure.&#xD;
&#xD;
         10. Symptomatic, unresolved multi-vessel coronary artery disease (CAD) or unprotected left&#xD;
             main coronary artery disease requiring stenting or Coronary Artery Bypass Grafting&#xD;
             (CABG).&#xD;
&#xD;
         11. Cerebrovascular accident (CVA) within six months of planned implant procedure.&#xD;
&#xD;
         12. Unresolved severe symptomatic carotid stenosis (&gt; 70% by ultrasound).&#xD;
&#xD;
         13. Cardiogenic shock or hemodynamic instability requiring inotropes or mechanical support&#xD;
             devices at the time of planned implant procedure.&#xD;
&#xD;
         14. Severe tricuspid regurgitation, tricuspid valve disease requiring surgery or severe&#xD;
             right ventricular dysfunction.&#xD;
&#xD;
         15. Hypertrophic or restrictive cardiomyopathy, constrictive pericarditis or any other&#xD;
             structural heart disease causing heart failure other than dilated cardiomyopathy of&#xD;
             either ischemic or non-ischemic etiology.&#xD;
&#xD;
         16. Any of the following: leukopenia, acute anemia, thrombocytopenia, history of bleeding&#xD;
             diathesis, or coagulopathy if cannot be adequately treated.&#xD;
&#xD;
         17. History of endocarditis within six months of planned implant procedure.&#xD;
&#xD;
         18. Active systemic infection requiring antibiotic therapy.&#xD;
&#xD;
         19. Known hypersensitivity or contraindication to procedural or post-procedural&#xD;
             medications (e.g., contrast solution, anti-coagulation therapy) which cannot be&#xD;
             adequately managed medically or hypersensitivity to nickel or titanium.&#xD;
&#xD;
         20. Patient is undergoing hemodialysis due to chronic renal failure.&#xD;
&#xD;
         21. Patient has pulmonary arterial hypertension (fixed PAS &gt;70mmHg).&#xD;
&#xD;
         22. Patient has COPD and is on home oxygen.&#xD;
&#xD;
         23. Patient refuses blood transfusions.&#xD;
&#xD;
         24. Pregnant, lactating, or planning pregnancy within next 12 months.&#xD;
&#xD;
         25. Participating or planning participation in an investigational drug or another device&#xD;
             study.&#xD;
&#xD;
         26. Patient or legal guardian unable or unwilling to give informed consent.&#xD;
&#xD;
         27. Patient unable or unwilling to comply with study required testing and follow-up&#xD;
             visits.&#xD;
&#xD;
         28. Patients with non-cardiac co-morbidities that are likely to result in a life&#xD;
             expectancy of less than one year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Honor Health Scottsdale Shea Medical Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northshore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health - Harrisburg Hospital</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Heart &amp; Vascular Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Center</name>
      <address>
        <city>Bedford Park</city>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyon University Hospital</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsche Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Heart Center Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ferrarotta - Catania</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pisa University</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <zip>56-20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinksa University Hospital</name>
      <address>
        <city>Solna</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Zurich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 10, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <results_first_submitted>August 10, 2021</results_first_submitted>
  <results_first_submitted_qc>August 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 2, 2021</results_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ABT-CIP-10337</keyword>
  <keyword>Tendyne Bioprosthetic Mitral Valve System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT02321514/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT02321514/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 191 patients were enrolled and attempted TMVR procedure with Tendyne Mitral Valve System. The first subject was implanted on 24 November 2014. The last subject was implanted on 02 June 2020 and completed the 1-month follow-up evaluation on July 6, 2020.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tendyne Mitral Valve System</title>
          <description>Tendyne Mitral Valve System&#xD;
Patients will undergo transcatheter mitral valve replacement using Tendyne Mitral Valve system</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed Visit</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Exit</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tendyne Mitral Valve System</title>
          <description>Tendyne Mitral Valve System&#xD;
Patients will undergo transcatheter mitral valve replacement using Tendyne Mitral Valve system</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="191"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.1" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Participants were identified in both Race and Ethnicity</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA Class, III/IV</title>
          <description>NYHA functional classification system relates symptoms to everyday activities and the patient's quality of life.&#xD;
NYHA Class I: Subjects with cardiac disease but without resulting limitations of physical activity.&#xD;
NYHA Class II: Subjects with cardiac disease resulting in slight limitation of physical activity.&#xD;
NYHA Class III: Subjects with cardiac disease resulting in marked limitation of physical activity.&#xD;
NYHA Class IV: Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety Endpoint: Number of Participants With Composite of Device Success and Freedom From Device or Procedure Related Serious Adverse Events (SAEs)</title>
        <description>Device success and freedom from the following device- or procedure-related serious adverse events (SAEs) at 30 days post the index procedure, will be classified by the Clinical Events Committee (CEC):&#xD;
Cardiovascular death&#xD;
Reintervention caused by valve-related dysfunction&#xD;
Disabling stroke&#xD;
Myocardial infarction (MI)&#xD;
Life-threatening bleeding (BARC Type 2, 3, and 5)&#xD;
Major Vascular Complications&#xD;
Renal failure requiring dialysis&#xD;
Other device-related SAEs&#xD;
Other procedure-related SAEs</description>
        <time_frame>30 days post-index procedure</time_frame>
        <population>The number of participants analyzed includes subjects who were available at that time of analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Tendyne Mitral Valve System</title>
            <description>Tendyne Mitral Valve System&#xD;
Patients will undergo transcatheter mitral valve replacement using Tendyne Mitral Valve system</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: Number of Participants With Composite of Device Success and Freedom From Device or Procedure Related Serious Adverse Events (SAEs)</title>
          <description>Device success and freedom from the following device- or procedure-related serious adverse events (SAEs) at 30 days post the index procedure, will be classified by the Clinical Events Committee (CEC):&#xD;
Cardiovascular death&#xD;
Reintervention caused by valve-related dysfunction&#xD;
Disabling stroke&#xD;
Myocardial infarction (MI)&#xD;
Life-threatening bleeding (BARC Type 2, 3, and 5)&#xD;
Major Vascular Complications&#xD;
Renal failure requiring dialysis&#xD;
Other device-related SAEs&#xD;
Other procedure-related SAEs</description>
          <population>The number of participants analyzed includes subjects who were available at that time of analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Performance Endpoint: Number of Participants With MR Grade ≤ 2</title>
        <description>Proportion of subjects with mitral regurgitation (MR) grade ≤ 2, per echocardiography core laboratory will be assessed.&#xD;
MR severity is graded on a scale of 0+ to 4+ where 0+ means absence of mitral regurgitation, 1+ is mild, 2+ is moderate, 3+ is moderate-to-severe and 4+ is severe.</description>
        <time_frame>30 days post-index procedure</time_frame>
        <population>The number of participants analyzed includes subjects who were available at that time of analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Tendyne Mitral Valve System</title>
            <description>Tendyne Mitral Valve System&#xD;
Patients will undergo transcatheter mitral valve replacement using Tendyne Mitral Valve system</description>
          </group>
        </group_list>
        <measure>
          <title>Performance Endpoint: Number of Participants With MR Grade ≤ 2</title>
          <description>Proportion of subjects with mitral regurgitation (MR) grade ≤ 2, per echocardiography core laboratory will be assessed.&#xD;
MR severity is graded on a scale of 0+ to 4+ where 0+ means absence of mitral regurgitation, 1+ is mild, 2+ is moderate, 3+ is moderate-to-severe and 4+ is severe.</description>
          <population>The number of participants analyzed includes subjects who were available at that time of analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tendyne Mitral Valve System</title>
          <description>Tendyne Mitral Valve System&#xD;
Patients will undergo transcatheter mitral valve replacement using Tendyne Mitral Valve system</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Blood loss not requiring transfusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Blood loss requiring transfusion</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Supratherapeutic INR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Other - Cytokine reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Conduction defect/cardiac arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Decreased LV function and/or cardiac output</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Device erosion, migration or malposition</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Heart Failure, Worsening</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Mitral valve regurgitation, worsening</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Multiple Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Paravalvular leak</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Thrombosis, Device</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Other - Cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Blood loss requiring transfusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Liver failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Other - Gastrointestinal/Digestive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Other - Genitourinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Blood loss not requiring transfusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>HEENT- Blood loss not requiring transfusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>HEENT- Blood loss requiring transfusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Liver failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Multiple Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Renal insufficiency or failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Vascular &amp; access-related complications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Other - Coagulopathy- clotting disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Other - Increased CT output</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Other - thoracic drainage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Other - unable to remove chest tube</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal lab values</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Renal insufficiency or failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other - Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Embolism, Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Other - Neurologic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal insufficiency or failure</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Other - Genitourinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Blood loss requiring transfusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Heart Failure, Worsening</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Respiratory Difficulty</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Respiratory Insufficiency/Failure</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Other - Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blood loss not requiring transfusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Vascular &amp; access-related complications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding complications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Blood loss requiring transfusion</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Vascular &amp; access-related complications</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Vascular &amp; access-related complications - Transapical</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Decreased LV function and/or cardiac output</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Paravalvular leak</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other - Gastrointestinal/Digestive</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal lab values</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal insufficiency or failure</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Respiratory Difficulty</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="191"/>
              </event>
              <event>
                <sub_title>Other - Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="191"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karine Miquel, PhD</name_or_title>
      <organization>Abbott</organization>
      <phone>+32 479 600 107</phone>
      <email>karine.miquel@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

